CAD 1.69
(-3.98%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 778.48 Million USD | -20.34% |
2022 | 977.31 Million USD | -3.08% |
2021 | 1 Billion USD | -35.37% |
2020 | 1.56 Billion USD | 227.82% |
2019 | 475.89 Million USD | -9.11% |
2018 | 523.6 Million USD | 380.55% |
2017 | 108.95 Million USD | 248.65% |
2016 | 31.25 Million USD | 3118.36% |
2015 | 971.04 Thousand USD | 27.4% |
2014 | 762.17 Thousand USD | 2663.6% |
2013 | 27.57 Thousand CAD | 164.32% |
2012 | 10.43 Thousand USD | -5.8% |
2011 | 11.07 Thousand USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 778.45 Million USD | 2.39% |
2023 FY | 778.48 Million USD | -20.34% |
2023 Q4 | 778.48 Million USD | -10.5% |
2023 Q3 | 869.81 Million USD | -7.19% |
2023 Q2 | 937.2 Million USD | -6.34% |
2023 Q1 | 1 Billion USD | 2.39% |
2022 Q4 | 977.31 Million USD | 0.84% |
2022 FY | 977.31 Million USD | -3.08% |
2022 Q1 | 1.02 Billion USD | 2.08% |
2022 Q2 | 991.23 Million USD | -3.7% |
2022 Q3 | 969.12 Million USD | -2.23% |
2021 Q2 | 1.29 Billion USD | -19.37% |
2021 Q1 | 1.6 Billion USD | 2.6% |
2021 Q4 | 1 Billion USD | -12.96% |
2021 Q3 | 1.15 Billion USD | -10.23% |
2021 FY | 1 Billion USD | -35.37% |
2020 Q3 | 972.32 Million USD | 46.15% |
2020 Q2 | 665.27 Million USD | 35.91% |
2020 Q1 | 489.49 Million USD | 2.86% |
2020 FY | 1.56 Billion USD | 227.82% |
2020 Q4 | 1.56 Billion USD | 60.44% |
2019 FY | 475.89 Million USD | -9.11% |
2019 Q1 | 507.47 Million USD | -3.08% |
2019 Q3 | 550.84 Million USD | -0.23% |
2019 Q2 | 552.12 Million USD | 8.8% |
2019 Q4 | 475.89 Million USD | -13.61% |
2018 FY | 523.6 Million USD | 380.55% |
2018 Q4 | 523.6 Million USD | 102.34% |
2018 Q3 | 258.78 Million USD | 13.49% |
2018 Q2 | 228.02 Million USD | 79.19% |
2018 Q1 | 127.25 Million USD | 16.79% |
2017 Q3 | 85.1 Million USD | 112.78% |
2017 Q4 | 108.95 Million USD | 28.03% |
2017 FY | 108.95 Million USD | 248.65% |
2017 Q1 | 32.17 Million USD | 2.96% |
2017 Q2 | 39.99 Million USD | 24.31% |
2016 FY | 31.25 Million USD | 3118.36% |
2016 Q4 | 31.25 Million USD | 207.59% |
2016 Q3 | 10.16 Million USD | 27.47% |
2016 Q1 | 7.94 Million USD | 718.69% |
2016 Q2 | 7.97 Million USD | 0.26% |
2015 FY | 971.04 Thousand USD | 27.4% |
2015 Q4 | 971.04 Thousand USD | -18.33% |
2015 Q3 | 1.18 Million USD | -1.09% |
2015 Q2 | 1.2 Million USD | -0.06% |
2015 Q1 | 1.2 Million USD | 57.8% |
2014 FY | 762.17 Thousand USD | 2663.6% |
2014 Q4 | 762.17 Thousand USD | 23.73% |
2014 Q3 | 615.99 Thousand USD | 2214.8% |
2014 Q2 | 26.61 Thousand USD | -3.51% |
2014 Q1 | 27.57 Thousand USD | -72.39% |
2013 Q2 | 7605.87 USD | -27.1% |
2013 Q1 | 10.43 Thousand USD | 258.47% |
2013 FY | 27.57 Thousand CAD | 164.32% |
2013 Q4 | 99.9 Thousand USD | 145.6% |
2013 Q3 | 40.67 Thousand USD | 434.8% |
2012 FY | 10.43 Thousand USD | -5.8% |
2012 Q1 | 11.07 Thousand USD | -40.98% |
2012 Q4 | 2910.70 USD | -80.84% |
2012 Q3 | 15.19 Thousand USD | -50.64% |
2012 Q2 | 30.77 Thousand USD | 177.87% |
2011 FY | 11.07 Thousand USD | 0.0% |
2011 Q2 | 48.28 Thousand USD | 0.0% |
2011 Q4 | 18.76 Thousand USD | 175.84% |
2011 Q3 | 6803.25 USD | -85.91% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aurora Cannabis Inc. | 236.8 Million CAD | -228.749% |
Avicanna Inc. | 13.99 Million CAD | -5461.02% |
Avant Brands Inc. | 33.22 Million CAD | -2243.147% |
Cardiol Therapeutics Inc. | 8.45 Million CAD | -9108.504% |
Crescita Therapeutics Inc. | 5.77 Million CAD | -13377.961% |
Knight Therapeutics Inc. | 198.62 Million CAD | -291.944% |
MediPharm Labs Corp. | 10.93 Million CAD | -7021.176% |
OrganiGram Holdings Inc. | 26.83 Million CAD | -2801.338% |
Canopy Growth Corporation | 799.82 Million CAD | 2.668% |
Willow Biosciences Inc. | 3.23 Million CAD | -23949.645% |
Auxly Cannabis Group Inc. | 210.85 Million CAD | -269.201% |